1
Natural Products Pharm. Lab, National Pharmaceutical Engineering Research Center, China State Institute of Pharmaceutical Industry, Zhangjiang Hi-Tech Park, Pudong New District, Shanghai, People's Republic of China
1
Natural Products Pharm. Lab, National Pharmaceutical Engineering Research Center, China State Institute of Pharmaceutical Industry, Zhangjiang Hi-Tech Park, Pudong New District, Shanghai, People's Republic of China
,
Ding-Zhong Song
1
Natural Products Pharm. Lab, National Pharmaceutical Engineering Research Center, China State Institute of Pharmaceutical Industry, Zhangjiang Hi-Tech Park, Pudong New District, Shanghai, People's Republic of China
,
Jie Yuan
1
Natural Products Pharm. Lab, National Pharmaceutical Engineering Research Center, China State Institute of Pharmaceutical Industry, Zhangjiang Hi-Tech Park, Pudong New District, Shanghai, People's Republic of China
,
Wu-Si Hao
1
Natural Products Pharm. Lab, National Pharmaceutical Engineering Research Center, China State Institute of Pharmaceutical Industry, Zhangjiang Hi-Tech Park, Pudong New District, Shanghai, People's Republic of China
,
Zhong-Bao Cui
1
Natural Products Pharm. Lab, National Pharmaceutical Engineering Research Center, China State Institute of Pharmaceutical Industry, Zhangjiang Hi-Tech Park, Pudong New District, Shanghai, People's Republic of China
1
Natural Products Pharm. Lab, National Pharmaceutical Engineering Research Center, China State Institute of Pharmaceutical Industry, Zhangjiang Hi-Tech Park, Pudong New District, Shanghai, People's Republic of China
› InstitutsangabenFunding This work was supported by China State Institute of Pharmaceutical Industry, National Pharmaceutical Engineering Research Center, Shanghai 201203, People's Republic of China.
Peripheral CB1R blockers without crossing the blood–brain barrier (BBB) have demonstrated therapeutic benefits in metabolic syndromes, including obesity. Among them is Alisol G, a tetracyclic triterpene from Alismatis rhizoma (zexie), which can effectively reduce the weight of obese mice. Results from CP55940-induced [35S] GTPγS cannabinoid-type 1 receptor (CB1R) binding assay show an IC50 of 34.8 μmol/L for Alisol G, implicating its role as a CB1R antagonist. The purpose of our study is to assess whether Alisol G could serve as a peripheral CB1R antagonist for obesity treatment. In this study, we build a simple, reliable, and sensitive method to detect the concentration of Alisol G in rat tissue by ultra-high-performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS). The results showed that Alisol G was mainly distributed in intestinal midgut, mucosa and small intestine, with little brain exposure. We suggested that intestine may be the main acting sites of Alisol G. Through comparison of brain and blood concentrations of Alisol G, our data showed that Alisol G cannot penetrate the BBB easily. In conclusion, Alisol G may represent a peripheral CB1R antagonist for the further treatment of obesity.
Keywords
Alisol G -
UHPLC-MS/MS -
tissue distribution -
blood–brain barrier
Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
References
1
Zhao J,
Xi JQ,
Zhang BB,
Song DZ,
Cheng ZH.
Pharmacokinetics and blood-brain barrier permeability of CB1R partial antagonist alisol g in rats [in Chinese]. Chinese J Pharm 2020; 51 (01) 95-102
2
Wu YK,
Yeh CF,
Ly TW,
Hung MS.
A new perspective of cannabinoid 1 receptor antagonists: approaches toward peripheral CB1R blockers without crossing the blood-brain barrier. Curr Top Med Chem 2011; 11 (12) 1421-1429
5
Christensen R,
Kristensen PK,
Bartels EM,
Bliddal H,
Astrup A.
Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 2007; 370 (9600): 1706-1713
9
Shi D,
Zhan X,
Yu X.
et al.
Inhibiting CB1 receptors improves lipogenesis in an in vitro non-alcoholic fatty liver disease model. Lipids Health Dis 2014; 13: 173
10
Kang A,
Hao H,
Zheng X.
et al.
Peripheral anti-inflammatory effects explain the ginsenosides paradox between poor brain distribution and anti-depression efficacy. J Neuroinflammation 2011; 8: 100
14
Wei LW,
Yuan Z,
Zhao M,
Han J,
Gu C,
Fu L.
Effect of cannabinoid receptor 1 on lipid metabolism in diet- induced obese mice. Sichuan Dong Wu 2018; 37 (01) 51-56
17
Jing HM,
Li GJ.
Progress in structure, function and toxicological research of blood-cerebrospinal fluid barrier. Zhongguo Yaolixue Yu Dulixue Zazhi 2010; 24: 562-565
18
Xu W,
Li X,
Lin N.
et al.
Pharmacokinetics and tissue distribution of five major triterpenoids after oral administration of Rhizoma Alismatis extract to rats using ultra high-performance liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal 2017; 146: 314-323